Cargando…
Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy
Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inh...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395273/ https://www.ncbi.nlm.nih.gov/pubmed/28442891 http://dx.doi.org/10.2147/DDDT.S110209 |
_version_ | 1783229850529562624 |
---|---|
author | Venur, Vyshak Alva Joshi, Monika Nepple, Kenneth G Zakharia, Yousef |
author_facet | Venur, Vyshak Alva Joshi, Monika Nepple, Kenneth G Zakharia, Yousef |
author_sort | Venur, Vyshak Alva |
collection | PubMed |
description | Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inhibitors like nivolumab and other PD-1/PD-L1 inhibitors provide an alternative approach for patients with mRCC. In this article, the authors review the safety profile and outcomes of phase 1, 2, and 3 clinical trials of nivolumab in mRCC. |
format | Online Article Text |
id | pubmed-5395273 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53952732017-04-25 Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy Venur, Vyshak Alva Joshi, Monika Nepple, Kenneth G Zakharia, Yousef Drug Des Devel Ther Review Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inhibitors like nivolumab and other PD-1/PD-L1 inhibitors provide an alternative approach for patients with mRCC. In this article, the authors review the safety profile and outcomes of phase 1, 2, and 3 clinical trials of nivolumab in mRCC. Dove Medical Press 2017-04-11 /pmc/articles/PMC5395273/ /pubmed/28442891 http://dx.doi.org/10.2147/DDDT.S110209 Text en © 2017 Venur et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Venur, Vyshak Alva Joshi, Monika Nepple, Kenneth G Zakharia, Yousef Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy |
title | Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy |
title_full | Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy |
title_fullStr | Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy |
title_full_unstemmed | Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy |
title_short | Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy |
title_sort | spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395273/ https://www.ncbi.nlm.nih.gov/pubmed/28442891 http://dx.doi.org/10.2147/DDDT.S110209 |
work_keys_str_mv | AT venurvyshakalva spotlightonnivolumabinthetreatmentofrenalcellcarcinomadesigndevelopmentandplaceintherapy AT joshimonika spotlightonnivolumabinthetreatmentofrenalcellcarcinomadesigndevelopmentandplaceintherapy AT nepplekennethg spotlightonnivolumabinthetreatmentofrenalcellcarcinomadesigndevelopmentandplaceintherapy AT zakhariayousef spotlightonnivolumabinthetreatmentofrenalcellcarcinomadesigndevelopmentandplaceintherapy |